复发难治性多发性骨髓瘤:全面综述
本文综述复发难治性多发性骨髓瘤(RRMM)的治疗策略。患者多已接受含蛋白酶体抑制剂和/或免疫调节剂的方案,治疗目标是控制疾病、毒性可接受并维持患者认可的生活质量。新药与联合方案不断涌现,推动个体化治疗,使MM转为可控慢性病。综述围绕何时治疗、如何治疗、治疗多久三个问题提出决策框架。
要点
- RRMM治疗目标为疾病控制、毒性可接受及患者认可的生活质量。
- 治疗决策需综合既往用药、合并症、潜在不良事件及患者意愿。
- 新药整合使MM从致命疾病转变为可管理的慢性病。
核心结论
- 新药及联合方案不断拓宽RRMM治疗选择,支持更个体化的治疗决策。
- 将新药整合入治疗范式后,多发性骨髓瘤被视为可管理的慢性病。
研究设计与样本
- 本文为全面综述,聚焦复发难治性多发性骨髓瘤的新型药物及治疗挑战。
主要发现
- 多数RRMM患者已接受含蛋白酶体抑制剂和/或免疫调节剂的药物组合治疗。
- 新药与联合方案持续涌现,拓宽了RRMM的治疗选择。
临床怎么用
- 医生需结合既往治疗、合并症、潜在不良事件及患者意愿决定是否治疗、何时治疗及如何治疗。
- 综述尝试提出通用策略,回答何时治疗、如何治疗及治疗多久三个基本问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients with relapsed/refractory multiple myeloma (RRMM) have been treated with drug combinations including a proteasome inhibitor (PI) and/or an immunomodulatory drug (IMiD). The goal of therapy for such patients is therefore to achieve disease control with acceptable toxicity and patient-defined decent quality of life. Physicians face a difficult task not only deciding who to treat, but also when to treat and how to treat, utilizing knowledge of previously administered therapies, patient comorbidities, potential adverse events, and patient wishes to make such a critical decision. New drugs and combination regimens are continuously underway thus broadening the options for therapy and giving way to a more individualized approach for patients with RRMM. The integration of novel agents into the treatment paradigm has shifted the perception of multiple myeloma (MM) from an incurable, fatal disease to a manageable, chronic one. This comprehensive review addresses the results and challenges posed by many of the newer agents for the treatment of RRMM. It attempts to propose a universal strategy for optimal therapy decision-making thus answering three simple fundamental questions-when to treat, how to treat, and how long to treat for.
引用
- Bazarbachi AH, Al Hamed R, Malard F, et al. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019. PMID: 31455853. doi:10.1038/s41375-019-0561-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。